A groundbreaking therapeutic approach, drawing its origins from the rich biodiversity of the Amazon rainforest, is making significant strides as a potential treatment for debilitating and life-threatening intestinal failure conditions. This innovative development highlights a unique convergence of ancient botanical knowledge and cutting-edge scientific research, offering a beacon of hope for patients with conditions like microvillus inclusion disease (MVID) and short bowel syndrome with intestinal failure (SBS-IF). Massimo Radaelli, President & CEO of Napo Therapeutics, a subsidiary of Jaguar Health, spearheads this ambitious endeavor, aiming to bring this novel plant-derived medicine to patients across Europe and beyond.
Radaelli, a seasoned leader with over 35 years dedicated to the rare disease pharmaceutical sector, expressed his profound honor at receiving the Global CEO Excellence Award 2025-26 from European CEO. He views this recognition not just as a personal achievement but as a testament to his unwavering commitment to advancing orphan medicines and improving the lives of those affected by rare conditions. This award underscores the growing international attention and validation for the development of treatments for diseases that have historically been underserved by the pharmaceutical industry.
The devastating impact of intestinal failure cannot be overstated. For many patients, particularly infants and young children, the condition necessitates constant, life-sustaining intravenous administration of fluids, electrolytes, and nutrients through total parenteral nutrition (TPN). This regimen, often requiring up to 20 hours daily, seven days a week, is not without its severe complications. These can include a range of toxicities, mirroring those seen in chemotherapy, leading to serious health issues such as recurrent infections, metabolic imbalances, and detrimental effects on vital organs like the liver and kidneys. The reliance on parenteral support, while essential for survival, carries a significant morbidity and mortality risk, presenting a critical unmet medical need.
For MVID and SBS-IF, the therapeutic landscape remains starkly limited. While MVID currently has no approved treatments, a subset of SBS-IF patients can access options like teduglutide and GLP-2 analogs. However, these treatments do not address the fundamental need for a therapy that can significantly reduce the reliance on parenteral support. This is where crofelemer, a novel drug developed by Napo Therapeutics and its affiliate Napo Pharmaceuticals, emerges as a potential game-changer. Derived from the sap of the Croton lechleri tree, a species indigenous to the Amazon basin, crofelemer has demonstrated clinical proof-of-concept in these orphan intestinal failure indications. The prospect of a first-in-class oral medication that can lessen the burden of parenteral support holds the potential to dramatically improve the quality of life and even extend the survival of these vulnerable patients.
Significant progress is being made on both the clinical and business development fronts for crofelemer. An independent proof-of-concept study conducted in the United Arab Emirates (UAE) involving pediatric intestinal failure patients has shown promising results. After over a year of treatment, initial findings presented at the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition Annual Meeting in November 2025 indicated a modification of disease progression, with reductions in parenteral support ranging from an encouraging 12% to 37%. These results are being further bolstered by Jaguar Health’s ongoing pivotal, placebo-controlled trial in pediatric MVID patients, slated for completion in the second quarter of 2026.
Given the ultra-rare nature of MVID and the absence of existing approved therapies, Napo Therapeutics is actively pursuing Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA). This designation is crucial for accelerating the regulatory pathway to market in the United States. Concurrently, the company is seeking to leverage the European Medicines Agency’s (EMA) PRIME (PRIority MEdicines) program for MVID, aiming to expedite the approval process within the European Union.
Recognizing the commercial potential and the urgent need for these therapies, Napo Therapeutics is actively seeking strategic partnerships. The company is open to global or regional collaborations for the development and commercialization of crofelemer for both MVID and SBS-IF. This includes exploring licensing agreements, co-promotion opportunities, and strategic product acquisition deals. The immediate focus for value creation is MVID, due to the potential for accelerated regulatory approval. The global prevalence of MVID is estimated at approximately 200 patients, making even a small trial statistically meaningful and supportive of regulatory submission. SBS-IF, on the other hand, represents a substantial follow-on market opportunity, with an estimated 12,000 patients in the United States alone, indicating a broader commercial franchise potential.
The development pathway for botanical drugs like crofelemer offers distinct advantages. Crofelemer’s active ingredient is sustainably sourced from the red bark sap of the Croton lechleri tree, a practice deeply rooted in the traditional medicinal knowledge of indigenous Amazonian communities. This approach not only taps into a valuable natural resource but also fosters sustainable sourcing practices. Crofelemer is already known for its role in Mytesi, Jaguar Health’s FDA-approved prescription drug for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS. Mytesi stands as the sole oral product approved under the FDA’s Botanical Guidance.
The regulatory framework for botanical drugs provides a unique intellectual property (IP) shield. Unlike conventional drugs that protect a specific molecule, the IP for a botanical drug encompasses the entire integrated manufacturing and quality control system. This comprehensive approach makes it exceedingly difficult for generic versions to enter the market, offering a more robust and enduring market exclusivity. Furthermore, botanical drug development benefits from a pre-existing safety profile derived from historical human exposure, which can reduce the risk of late-stage safety failures that frequently derail conventional New Chemical Entity (NCE) programs. This inherent de-risking of the clinical development process can lead to more efficient and predictable timelines for bringing novel therapies to patients. The journey of crofelemer from the Amazon to advanced clinical trials exemplifies the powerful synergy between nature’s bounty and scientific innovation, promising a brighter future for those battling rare and life-altering intestinal diseases.
